BioCardia, Inc. (BCDA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration agreement revenue | - | - | - | 3 |
| Selling, general and administrative | 683 | 1,196 | 825 | 852 |
| Research and development | 1,368 | 1,530 | 931 | 800 |
| Total costs and expenses | 2,051 | 2,726 | 1,756 | 1,652 |
| Operating loss | -2,051 | -2,726 | -1,756 | -1,649 |
| Total other income, net | 2 | 14 | 19 | 3 |
| Net loss | -2,049 | -2,712 | -1,737 | -1,646 |
| Net loss per share, basic and diluted (in dollars per share) | -0.4 | -0.59 | -0.61 | -0.88 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 5,059,736 | 4,635,764 | 2,827,492 | 1,877,069 |